Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01595516 · ClinicalTrials.gov registry record · Phase 4
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
A Phase 4 study of Hypertension and Prehypertension, sponsored by University of Colorado, Boulder.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT01595516: Completed Phase 4 study of Hypertension and Prehypertension, sponsored by University of Colorado, Boulder.
NCT01595516 is a Phase 4 study of Hypertension and Prehypertension that has completed, run by University of Colorado, Boulder. The registered enrollment target is 44 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01595516, a Phase 4 study of Hypertension and Prehypertension, has completed, sponsored by University of Colorado, Boulder.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-PA with nebivolol is mediated, in part, by the compound's antioxidant properties.
Primary Outcome
Resting heart rate in the seated position
Conditions Studied
Interventions
- DRUG Placebo
- OTHER Saline
- DRUG Nebivolol
- DRUG Metoprolol
- OTHER Bradykinin
Study Locations (1)
Colorado
- UC-Boulder Clinical and Translational Research Center - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-02 |
| Est. Completion | 2017-10 |
| Phase | Phase 4 |
What the finished NCT01595516 record still lists
NCT01595516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01595516 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01595516 about?
NCT01595516 is a clinical study titled "Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)". The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-P...
What is the current status of trial NCT01595516?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2012-02. Estimated completion is 2017-10.
What conditions does trial NCT01595516 study?
This clinical trial studies the following conditions: Hypertension, Prehypertension.
What interventions are being tested in trial NCT01595516?
The interventions under investigation include: Placebo (DRUG), Saline (OTHER), Nebivolol (DRUG), Metoprolol (DRUG), Bradykinin (OTHER).
Who is sponsoring clinical trial NCT01595516?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01595516 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01595516's enrollment target sits among peer trials
44 381st of 470 higher than 88 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia